Vaxcyte

Vaxcyte Up on Pneumococcal Conjugate Vaccine Data
Vaxcyte Up on Pneumococcal Conjugate Vaccine Data
Zacks.com
Vaxcyte
vaccines
clinical trials
pneumococcal disease
VAX-24
Flag link:
Vaxcyte strengthens case for experimental pneumococcal vaccine
Vaxcyte strengthens case for experimental pneumococcal vaccine
BioPharma Dive
Vaxcyte
vaccines
clinical trials
pneumococcal disease
Flag link:
Biotech heads towards big catalysts
Biotech heads towards big catalysts
EP Vantage
biotech
clinical trials
Alnylam Pharmaceuticals
Arcus Biosciences
Argenx
Arrowhead Pharmaceuticals
Axsome Therapeutics
Bavarian Nordic
FibroGen
Gilead Sciences
Incyte
Morphic Therapeutic
PTC Therapeutics
Syndax Pharmaceuticals
Travere Therapeutics
Vaxcyte
Flag link:
Biotech’s key upcoming clinical results
Biotech’s key upcoming clinical results
EP Vantage
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
Flag link:
After going head-to-head with Prevnar 20, Vaxcyte's 24-valent pneumococcal shot will seek a pivotal win
After going head-to-head with Prevnar 20, Vaxcyte's 24-valent pneumococcal shot will seek a pivotal win
Endpoints
Vaxcyte
vaccines
VAX-24
pneumococcal disease
Pfizer
Prevnar 20
clinical trials
Flag link:
Slaoui steps down from two more biotechs after harassment claim
Slaoui steps down from two more biotechs after harassment claim
BioPharma Dive
Moncef Slaoui
GSK
Galvani
Vaxcyte
Centessa Pharmaceuticals
sexual harassment
Flag link:
The biotech IPOs keep coming at chart-topping levels — with no slowdown in sight
The biotech IPOs keep coming at chart-topping levels — with no slowdown in sight
Endpoints
biotech
IPOs
Repare Therapeutics
Forma Therapeutics
Avidity Biosciences
Vaxcyte
SK Biopharmaceuticals
Generation Bio
Royalty Pharma
Flag link:
The pandemic IPOs keep rolling, as Generation, Avidity, Vaxcyte each claim 200M+
The pandemic IPOs keep rolling, as Generation, Avidity, Vaxcyte each claim 200M+
Endpoints
biotech
IPOs
Generation Bio
Avidity Biosciences
Vaxcyte
Burning Rock
Flag link: